{"id":"W4295445025","doi":"10.1111/cts.13387","title":"Manufacturing‐dependent change in biological activity of the <scp>TLR4</scp> agonist <scp>GSK1795091</scp> and implications for lipid A analog development","year":2022,"lang":"en","type":"article","venue":"Clinical and Translational Science","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; Sanofi Genzyme; Merck Sharp and Dohme; EMD Serono; Genentech; MacroGenics; Silverback Therapeutics; Principia Biopharma; Puma Biotechnology; F-star Therapeutics; Aminex Therapeutics; BeiGene; Mirati Therapeutics; Jounce Therapeutics; Wellcome Trust; Array BioPharma; Five Prime Therapeutics; Conquer Cancer Foundation; Taiho Pharmaceutical; National Institutes of Health; Regeneron Pharmaceuticals; BioMarin Pharmaceutical; Daiichi Sankyo Europe; National Cancer Institute; Intuitive Surgical; Gilead Sciences; Bristol-Myers Squibb; ImmunoMedics; Adenoid Cystic Carcinoma Research Foundation; Eli Lilly and Company; American Society of Clinical Oncology; GlaxoSmithKline; Gateway for Cancer Research; Exelixis; Sanofi; Abbott Laboratories; Incyte; Pfizer; Amgen","keywords":"Medicine; Pharmacodynamics; Agonist; Chills; Adverse effect; Cytokine; Pharmacology; Pharmacokinetics; Nausea; TLR4; Clinical endpoint; Immunotherapy; Clinical trial; Immune system; Internal medicine; Immunology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002538641,0.0003892601,0.0003241218,0.0002096085,0.0001618724,0.000705213,0.0003633618,0.0005215582,0.002035137],"category_scores_gemma":[0.001633938,0.0002373043,0.000562866,0.0002373011,0.0004231728,0.0004172493,0.0002309848,0.0007323976,0.0004752813],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005643271,"about_ca_system_score_gemma":0.0005579104,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004084401,"about_ca_topic_score_gemma":0.000839756,"domain_scores_codex":[0.9989428,0.0004382182,0.000114476,0.0001254009,0.0002884472,0.00009080204],"domain_scores_gemma":[0.9991422,0.0002368841,0.0004103954,0.0001040865,0.0000581645,0.0000482738],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.03489511,0.004068693,0.0159706,0.0007144624,0.0004240439,0.0005535227,0.0001414983,0.004006408,0.7751058,0.0007009538,0.002035497,0.1613834],"study_design_scores_gemma":[0.02700481,0.3518853,0.1035167,0.0001548213,0.00104307,0.003381429,0.0002170567,0.006999231,0.4685236,0.001050624,0.03609626,0.0001272968],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912673,0.00259901,0.001799016,0.0003274763,0.00009090602,0.0006848975,0.0004294002,0.00005757859,0.002744402],"genre_scores_gemma":[0.994849,0.0007878316,0.002531939,0.0003131056,0.00003925713,0.0002452287,0.0004668336,0.0000211426,0.0007455925],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002538641,"threshold_uncertainty_score":0.01342577,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07507872474596153,"score_gpt":0.3287074352560683,"score_spread":0.2536287105101068,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}